One of the relevant features of BiOMViS’ technology is the rapidity with which OMV-based vaccine formulations can be produced and tested. Soon after the sequence and the 3D structure of …
BiOMViS has tested the potential of its OMV-based platform technology to develop a vaccine against Staphylococcus aureus. S. aureus is a human pathogen responsible for community and hospital-acquired invasive diseases. …
Tumors develop as a consequence of gene mutations that alter cellular morphology and metabolism. These mutations, that give tumors a selective growth advantage over healthy tissues, potentially represent tumors’ “Achilles’ …
BiOMViS vaccine platform is based on Outer Membrane Vesicles (OMVs) released by a non-pathogenic E. coli derivative (E. coli BL21Δ60) created by a Synthetic Biology approach. The amazing properties of …